Company Overview
Snapshot
Founded in February 2021 by Seth Salpeter, Immunyx Pharma operates with 1–10 employees. The company has secured funding across one round from one investor, VLX Ventures. In February 2021, Immunyx Pharma developed a technology for targeting neutrophils as a therapy for severe COVID-19 infection.
Business overview
Immunyx Pharma is a drug development company focused on modulating neutrophil function to treat diseases. The company utilizes a platform technology that specifically manipulates neutrophils using targeted nanoparticles to develop new therapies. Immunyx Pharma serves the pharmaceutical and biotechnology industries, operating within the Health Tech & Life Sciences sector, specifically in Drugs Discovery & Development.
Log in to access full profile ›Company Intelligence Q&A
- What is Immunyx Pharma's core focus?
- Immunyx Pharma is a drug development company focused on modulating neutrophil function to treat various diseases using its proprietary platform technology.
- Who founded Immunyx Pharma?
- Immunyx Pharma was co-founded by Seth Salpeter in February 2021.
- What is the basis of Immunyx Pharma's neutrophil-targeting technology?
- Immunyx Pharma's neutrophil-targeting technology is based on years of basic and translational research conducted by professors Zvika Granot and Zvi Fridlender at the Hebrew University.
- What significant technology development did Immunyx Pharma achieve in early 2021?
- In February 2021, Immunyx Pharma developed a technology for targeting neutrophils as a therapy for severe COVID-19 infection.